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CORRESPONDENCE
Letters to the Editor
Simvastatin and
Plaque Inflammation
We read with great interest the study by Tahara et al. (1) published
recently in the Journal and concerned with tracking statin-induced
inflammation reduction in atherosclerotic plaques using fluorode-
oxyglucose positron emission tomography (FDG-PET).
Although this study highlights the very real potential of
FDG-PET imaging of atherosclerosis for the detection and
monitoring of plaque inflammation, we would like to comment on
several aspects of the study’s methodology that may have impacted
the results seen by the investigators.
First, we believe that the time between injection of FDG and
PET image acquisition was too short at 1 h. Previous studies have
shown that a circulation time for FDG in excess of 2 h gives a
much higher target (plaque)-to-background (blood) ratio (2–4). A
high target-to-blood ratio is crucial to ensuring proper region-of-
interest placement and thus accurate quantification of plaque FDG
uptake.
Second, especially given their choice of early imaging time
point, the researchers should have attempted to correct the plaque
FDG uptake for blood activity. This is typically achieved by
measurement of the mean of several blood values from a large vein.
This value is then divided into the plaque standardized uptake
value to yield a tissue-to-blood ratio of FDG uptake. This is the
method adopted in previous studies, and in the elegant study by
Tawakol et al. (2) which appears in the same issue of the Journal.
Although Tahara et al. (1) defend their decision not to do this, we
do not believe the reasons they give justify the absence of a
correction. The investigators suggest that the patchy uptake of
vascular FDG and the nonvisualization of veins means that the
blood-pool signal is likely insignificant. More likely is the fact that
atherosclerosis is a diffuse condition, taking up FDG variably along
the length of the vessel. Additionally, we believe that blood-pool
activity would still be significant at such an early imaging time
point, with a standardized uptake value well above other back-
ground structures.
Additionally, we suggest the use of a combined PET/computed
tomography scanner may have made accurate anatomical coregis-
tration easier. This will be particularly important when extending
this kind of study into the aorta and other vascular beds.
Finally, we contend that the investigators might have chosen a
more potent anti-inflammatory drug than low-dose simvastatin for
testing their hypothesis that FDG-PET imaging could track
inflammatory change within plaque. Although their study yielded
positive results, the magnitude of the effect would surely have been
greater with a higher dose of a more powerful statin, and this
might have answered some of the questions with which the
researchers were left at the end of their study, such as why the
FDG reduction induced by statin treatment correlated more
closely with the high-density lipoprotein increase than with
low-density lipoprotein decrease.
Tahara et al. (1) should be congratulated on completing such an
exciting piece of work, but we suggest that for future studies in this
area a longer FDG circulation time with appropriate blood activity
correction should be used. If these ideas had been adopted by the
investigators in their current study, we believe they would have
shown an even greater positive impact of the statin upon plaque
inflammation as assessed by FDG-PET.
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Reply
We thank Drs. Rudd, Machac, and Fayad for having interest in
our recent study (1). There is a growing body of evidence that
fluorodeoxyglucose positron emission tomography (FDG-PET)
imaging has a great potential for noninvasively detecting and
quantifying plaque inflammation in humans. Anecdotal studies
have reported increased FDG uptake in the regions of the aorta
and large arteries in patients who had undergone FDG-PET
imaging for cancer diagnosis and staging (2,3). Recently, we and
others have validated FDG uptake in the arterial wall (i.e., plaques)
by coregistering FDG-PET imaging with structural imaging, such
as computed tomography and magnetic resonance imaging
(1,4–7). More importantly, histological examination of the end-
arterectomized specimen obtained from the FDG uptake-
documented carotid arteries has provided solid evidence that the
vascular FDG uptake is associated with macrophage accumulation,
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